Answers are grounded in this paper and cite their sources.
A proportion of patients with CSU on omalizumab may benefit from long treatment duration (at least 24 weeks). Late responding patients were more likely to have low IgE, high BMI, less disease control, and be a younger age at baseline. A proportion of patients with CSU on omalizumab may benefit from long treatment duration (at least 24 weeks). Late responding patients were more likely to have low IgE, high BMI, less disease control, and be a younger age at baseline.
No takes yet. Share an insight, caveat, or question.
Mosnaim et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: